The Exchange has sought clarification from Alkem Laboratories Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Alkem Laboratories to clarify discrepancies found in the financial results filed in XBRL format for the quarter ended 31-March-2025, under Regulation 33 of SEBI Listing Regulations. This is a procedural query related to the format/accuracy of the XBRL submission of quarterly results. The company has not yet responded, and its clarification is awaited. No specific financial figures or operational issues have been mentioned — the concern is limited to the XBRL filing quality.
This appears to be a routine procedural clarification and is unlikely to materially impact the stock. Investors should monitor for the company's response to confirm there are no underlying financial reporting issues.